Victory Capital Management Inc. Sells 9,038 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Victory Capital Management Inc. cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 9.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 88,756 shares of the medical research company's stock after selling 9,038 shares during the quarter. Victory Capital Management Inc.'s holdings in IQVIA were worth $17,441,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Farther Finance Advisors LLC increased its stake in IQVIA by 35.2% in the third quarter. Farther Finance Advisors LLC now owns 407 shares of the medical research company's stock valued at $96,000 after acquiring an additional 106 shares during the last quarter. Impax Asset Management Group plc boosted its holdings in shares of IQVIA by 9.7% in the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company's stock worth $423,885,000 after purchasing an additional 157,809 shares in the last quarter. Capital Performance Advisors LLP bought a new position in shares of IQVIA during the 3rd quarter valued at about $27,000. Assetmark Inc. raised its holdings in shares of IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company's stock valued at $54,000 after buying an additional 196 shares in the last quarter. Finally, Atria Investments Inc lifted its position in IQVIA by 6.6% in the 3rd quarter. Atria Investments Inc now owns 20,404 shares of the medical research company's stock worth $4,835,000 after buying an additional 1,261 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on IQV shares. Morgan Stanley lifted their price target on shares of IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. Truist Financial reiterated a "buy" rating and issued a $263.00 target price (up previously from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Stephens initiated coverage on shares of IQVIA in a research report on Friday, December 20th. They set an "overweight" rating and a $250.00 price target for the company. Robert W. Baird decreased their price objective on IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, January 21st. Finally, Stifel Nicolaus dropped their target price on IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a report on Friday, February 7th. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, IQVIA presently has a consensus rating of "Moderate Buy" and an average target price of $249.05.

Remove Ads

IQVIA Stock Performance

IQVIA stock opened at $183.72 on Wednesday. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $261.72. The stock's 50 day simple moving average is $197.36 and its two-hundred day simple moving average is $211.78. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a market cap of $32.39 billion, a price-to-earnings ratio of 24.50, a PEG ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.